Señales en vivo de NFX.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:26):

Stats
Volumen de hoy	1.11M
Volumen promedio	2.21M
Capitalización de mercado	1.54M
EPS	£0 ( 2023-05-22 )
Próxima fecha de ganancias	( £0 ) 2024-06-29
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	0
ATR14	£0 (0.00%)

Nuformix PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nuformix PLC Finanzas

Annual	2023
Ingresos:	£0
Beneficio Bruto:	£-36 749.00 (0.00 %)
EPS:	£-0.000800

FY	2023
Ingresos:	£0
Beneficio Bruto:	£-36 749.00 (0.00 %)
EPS:	£-0.000800

FY	2022
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.00130

FY	2022
Ingresos:	£50 000.00
Beneficio Bruto:	£48 305.00 (96.61 %)
EPS:	£-0.00190

Financial Reports:

No articles found.

Nuformix PLC

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.